Edgewise Therapeutics, Inc. Income Tax Expense
Edgewise Therapeutics, Inc. (EWTX) reported Income Tax Expense of $4.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-02-26
- Edgewise Therapeutics, Inc. income tax expense (benefit) for fiscal 2025 was $4.00K, a 33.33% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. income tax expense (benefit) for fiscal 2024 was $3.00K, a 25.00% decline from fiscal 2023.
- Edgewise Therapeutics, Inc. income tax expense (benefit) for fiscal 2023 was $4.00K.
- Edgewise Therapeutics, Inc. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $4.00K 10-K · filed 2026-02-26 | |
| 2024-12-31 | $3.00K 10-K · filed 2026-02-26 | $0.00 10-K · filed 2025-03-03 |
| 2023-12-31 | $4.00K 10-K · filed 2026-02-26 | $0.00 10-K · filed 2024-02-22 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-23 | |
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |